A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort

The maximum tolerated dose of the panobinostat and carfilzomib combination in patients with relapsed/refractory multiple myeloma (RRMM) was not reached in our previous dose‐escalation study. We report additional dose levels in the phase I/II, single‐arm, multicenter, standard 3 + 3 dose‐escalation e...

Descripción completa

Detalles Bibliográficos
Autores principales: Berdeja, Jesus G., Gregory, Tara K., Faber, Edward A., Hart, Lowell L., Mace, Joseph R., Arrowsmith, Edward R., Flinn, Ian W., Matous, Jeffrey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986798/
https://www.ncbi.nlm.nih.gov/pubmed/33421178
http://dx.doi.org/10.1002/ajh.26088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986798/
https://www.ncbi.nlm.nih.gov/pubmed/33421178
http://dx.doi.org/10.1002/ajh.26088

Ejemplares similares